---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-082850"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-07-13T11:11:25+00:00"
generated_at: "2026-07-13T11:15:30.661646+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Armata receives FDA agreement on pediatric study plan for AP-SA02 in S. aureus bacteremia

## Summary
- FDA agreed on Initial Pediatric Study Plan (iPSP) for AP-SA02 as adjunct treatment for complicated S. aureus bacteremia in patients up to 17 years.
- iPSP agreement is a regulatory requirement that must be met before submitting a Biologics License Application (BLA).
- Pediatric studies will be deferred until adult Phase 3 safety/efficacy data are available; adult Phase 3 expected to start H2 2026.
- CEO Dr. Deborah Birx highlighted the milestone as addressing vulnerable pediatric populations with limited treatment options.
- AP-SA02 has QIDP and Fast Track designations; Phase 2a results presented at IDWeek 2025.

## SEC filing metadata
- accession: 0001104659-26-082850
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-07-13T11:11:25+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926082850/0001104659-26-082850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926082850/tm2620286d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-082850
- JSON: https://secwatch.observer/filing/0001104659-26-082850.json
- Plain text: https://secwatch.observer/filing/0001104659-26-082850.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.